USPTO Examiner JONES FOSTER ERICA NICOLE - Art Unit 1656

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18909568METHODS OF PREPARING A POSTBIOTIC COMPOSITIONOctober 2024January 2026Allow1550YesNo
18894709Compositions and Methods for Making Epigenetic ModificationsSeptember 2024March 2025Allow510YesNo
18750621High Fidelity Restriction EndonucleasesJune 2024October 2025Allow1610YesNo
18740177SYSTEM AND METHOD FOR PRESERVING ALGAEJune 2024September 2025Abandon1520YesNo
18444590Compositions and Methods for Making Epigenetic ModificationsFebruary 2024June 2024Allow400YesNo
18405861PROTEASE VARIANTS AND USES THEREOFJanuary 2024July 2024Allow710YesNo
18561170IDENTIFICATION OF AN alpha-1,2-FUCOSYLTRANSFERASE FOR THE IN VIVO PRODUCTION OF PURE LNFP-INovember 2023June 2025Allow1911YesNo
18121697Modified Yeast Microorganisms to Increase Yield of 3-Hydropropionic AcidMarch 2023October 2024Allow1911YesNo
18022140METHODS AND COMPOSITIONS FOR PURIFICATION OF TRIMERIC FUSION PROTEINSFebruary 2023December 2025Allow3410NoNo
18082128STABLE LIPASE FORMULATIONS AND METHODS THEREOFDecember 2022March 2025Abandon2720NoNo
18078159Methods for enzymatic production of glucosamine salts and the purification methods thereofDecember 2022March 2026Abandon3920NoNo
17914914COMBINED ANIMAL-DERIVED AND SYNTHETICALLY PRODUCED PANCREATIC ENZYME REPLACEMENT THERAPYSeptember 2022February 2026Abandon4011NoNo
17934765METHODSeptember 2022August 2025Abandon3530NoNo
17912111BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF LEUCINESeptember 2022October 2025Abandon3710NoNo
17895320ENGINEERED SPIDER SILK PROTEINS AND USES THEREOFAugust 2022February 2026Allow4110NoNo
17836735Treatment Of Psoriasis With Interferon Induced Helicase C Domain 1 (IFIH1) InhibitorsJune 2022November 2025Allow4120NoNo
17781124GENE ENGINEERING BACTERIA FOR PRODUCING L-ARGININE AND CONSTRUCTION METHOD AND APPLICATION OF GENE ENGINEERING BACTERIAMay 2022November 2025Allow4211YesNo
17747589CELL BASED SHEAR STRESS SENSORMay 2022October 2025Allow4121YesNo
17744646ENDOPHYTIC FUNGUS PSEUDOPHIALOPHORA ORYZAE P-B313 AND ITS APPLICATIONMay 2022October 2024Allow2920NoNo
17729752METHOD OF INDUCING EXPRESSION OF CALCIUM CHANNEL AND/OR CALCIUM PUMP, AND APPARATUS THEREFORApril 2022December 2025Allow4421YesNo
17699354T4 DNA Ligase Variants with Increased Ligation EfficiencyMarch 2022July 2025Allow4080YesNo
17642874PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONSMarch 2022June 2025Allow3911YesNo
17637443FOLATE PRODUCING STRAIN AND THE PREPARATION AND APPLICATION THEREOFFebruary 2022October 2025Abandon4411NoNo
17675556Gene Editing Nanocapsule and Preparation Method and Use ThereofFebruary 2022May 2024Allow2610YesNo
17590774RECOMBINANT MILK PROTEINS AND FOOD COMPOSITIONS COMPRISING THE SAMEFebruary 2022May 2025Abandon4001NoNo
17630627METHOD FOR PURIFYING ANTIBODY USING ADSORBENTJanuary 2022April 2025Abandon3901NoNo
17630579PROTEIN HAVING ACTIVITY OF CATALYZING alpha-1, 6 GLUCOSYL TRANSFER REACTIONJanuary 2022March 2026Abandon5021YesNo
17578681METHODS OF IMPROVING PROTEIN TITER IN CELL CULTUREJanuary 2022February 2024Allow2510YesNo
17628451METHODS AND PRODUCTS FOR TREATMENT OF GASTROINTESTINAL DISORDERSJanuary 2022October 2025Abandon4520NoNo
17623231VARIANT DIHYDRODIPICOLINATE REDUCTASE POLYPEPTIDE AND METHOD OF PRODUCING L-THREONINE USING THE SAMEDecember 2021July 2025Allow4311YesNo
17622068NOVEL LACTOBACILLUS PLANTARUM, LACTIC ACID BACTERIA COMPOSITION AND USE THEREOF FOR CURING OR PREVENTING HEAVY METAL RELATED DISEASESDecember 2021January 2026Abandon4921NoNo
17620990METHOD FOR PRODUCING EXOSOMES BY ELECTRICAL STIMULATIONDecember 2021June 2025Abandon4211NoNo
17555684SYSTEMS AND METHODS FOR REMOVING METHANE FROM A GAS STREAMDecember 2021September 2024Abandon3320YesNo
17554164COMPOSITIONS COMPRISING BACTERIAL STRAINSDecember 2021January 2025Abandon3701NoNo
17620324Co-Culture of Myxobacteria and Pseudomonas for Enhanced Production of Biosurfactants and Other MetabolitesDecember 2021December 2024Abandon3601NoNo
17615512PROBIOTIC COMPOSITIONS AND METHODS OF USENovember 2021June 2025Abandon4221NoNo
17615256Metabolomic Characterization of MicroorganismsNovember 2021January 2025Allow3730YesNo
17613147Detection of GlycosaminoglycansNovember 2021January 2026Abandon5021NoNo
17612870TREATMENT OF SENSORINEURAL DEAFNESSNovember 2021November 2025Abandon4830YesNo
17610250TARGETING SEQUENCES FOR PAENIBACILLUS-BASED ENDOSPORE DISPLAY PLATFORMNovember 2021November 2024Abandon3611NoNo
17609746COMPOSITION FOR PREVENTING OR TREATING OBESITY, COMPRISING PHOSPHOLIPASE A2 AS ACTIVE INGREDIENTNovember 2021March 2026Abandon5230NoNo
17493100RECOMBINANT MILK PROTEINSOctober 2021June 2025Abandon4410NoNo
17490486METHOD OF MANIPULATING PHAGES WITHIN THE BODY TO ATTACK INFECTIOUS TARGET CELLSSeptember 2021November 2025Abandon5030YesNo
17441888Compositions and Methods for Modifying Dystrophin GenesSeptember 2021November 2024Abandon3801NoNo
17440973WASTE TREATMENT SYSTEM AND WASTE TREATMENT METHODSeptember 2021October 2025Abandon4931YesNo
17437114POLYPEPTIDE VARIANTSSeptember 2021November 2024Allow3811NoNo
17394184MICROORGANISMS AND METHODS FOR PRODUCING BUTADIENE AND RELATED COMPOUNDS BY FORMATE ASSIMILATIONAugust 2021December 2024Abandon4101NoNo
17427764Lactobacillus Mudanjiangensis Strains And Cellulase Derived TherefromAugust 2021January 2025Allow4120NoNo
17423262METHOD FOR PRODUCING L-AMINO ACIDS USING MICROORGANISM CONTAINING NADP-DEPENDENT GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASEJuly 2021July 2024Allow3620YesNo
17366239EFFICIENT SELECTIVITY OF RECOMBINANT PROTEINSJuly 2021May 2025Abandon4720NoNo
17364632LACTOBACILLUS PARACASEI AND USES THEREOFJune 2021May 2024Allow3520YesNo
17416928DNA-BARCODED NUCLEOSOMES FOR CHROMATIN MAPPING ASSAYSJune 2021July 2025Allow4821YesNo
17351422FLUORESCENT ASSAY SYSTEMS FOR REAL-TIME MEASUREMENT OF PROTEIN UBIQUITINATION AND USES THEREOFJune 2021October 2025Abandon5231NoNo
17415600SLIDING CLAMP-BASED AFFINITY PURIFICATION SYSTEMS, METHODS OF MAKING AND USE THEREOFJune 2021November 2025Allow5321YesNo
17414604MALONIC SEMI-ALDEHYDE-PRODUCING YEASTSJune 2021September 2024Abandon3901NoNo
17309629BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMPJune 2021June 2025Allow4821YesNo
17337201METHOD FOR PRODUCING RARE FATTY ACID USING NOVEL ENZYME, AND NOVEL RARE FATTY ACIDJune 2021July 2025Abandon4921NoNo
17296932Improved Filamentous Fungal Host CellsMay 2021June 2025Allow4811NoNo
17296622TRANSMEMBRANE DOMAIN DERIVED FROM HUMAN LRRC24 PROTEINMay 2021November 2024Allow4221NoNo
17295400PURIFICATION OF IDURONATE-2-SULFATASE IMMUNOGLOBULIN FUSION PROTEINMay 2021June 2025Abandon4930NoNo
17294287G-TO-T BASE EDITORS AND USES THEREOFMay 2021May 2025Abandon4821NoNo
17289665NUCLEOBASE EDITORS COMPRISING GEOCAS9 AND USES THEREOFApril 2021November 2024Allow4311YesNo
17287135AN ANTIMICROBIAL COMPOSITION FOR SELECTIVELY INHIBITING GROWTH OF P. ACNES BACTERIAApril 2021May 2025Abandon4820YesNo
17227799High Fidelity Restriction EndonucleasesApril 2021April 2024Allow3610NoNo
17226693High Fidelity Restriction EndonucleasesApril 2021April 2024Allow3610YesNo
17272315PROCESS FOR BIOLOGICAL AMMONIA PRODUCTION BY NITROGEN FIXING CYANOBACTERIAFebruary 2021October 2025Abandon5520NoNo
17178805EVALUATING METHOD OF KETOSIS IN POSTPARTUM DAIRY COWSFebruary 2021December 2024Allow4630YesNo
17262350Artificial Hair Fiber, Method for Manufacturing Same, and Artificial HairJanuary 2021July 2025Abandon5431YesNo
17260984GENERATION OF ACYL AMINO ACIDSJanuary 2021June 2024Allow4120YesNo
17260483MEANS AND METHOD FOR THE REAL-TIME ANALYSIS OF HARVESTED CROPSJanuary 2021January 2025Abandon4820NoNo
17259147RNA PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND USES THEREOFJanuary 2021August 2025Allow5540YesNo
17258088MICROBIAL METHOD FOR PRODUCTION OF PROTEIN ISOLATE/CONCENTRATE FROM OILSEED CAKES/MEALSJanuary 2021January 2025Allow4821YesNo
17082876USE OF COMPOSITIONS OF WATER/ALCOHOL EXTRACTS OF ANTRODIA CINNAMOMEA CUT-LOG WOOD CULTIVATED FRUITING BODY AND SOLID-STATE CULTIVATED MYCELIUM AS AUXILIARIES FOR ANTI-CANCER AGENTSOctober 2020April 2025Abandon5440YesNo
16947959ALPHA-HEMOLYSIN VARIANTS AND USES THEREOFAugust 2020April 2024Abandon4321YesNo
16768055SynP61, A PRIMATE RETINAL PIGMENT EPITHELIUM CELL-SPECIFIC PROMOTERMay 2020June 2024Abandon4810NoNo
16639719USE OF ANTI-CRISPR POLYPEPTIDES FOR SPECIFIC ACTIVATION OF CAS NUCLEASESFebruary 2020December 2024Abandon5820YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner JONES-FOSTER, ERICA NICOLE - Prosecution Strategy Guide

Executive Summary

Examiner JONES-FOSTER, ERICA NICOLE works in Art Unit 1656 and has examined 47 patent applications in our dataset. With an allowance rate of 38.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner JONES-FOSTER, ERICA NICOLE's allowance rate of 38.3% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by JONES-FOSTER, ERICA NICOLE receive 1.85 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by JONES-FOSTER, ERICA NICOLE is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +39.1% benefit to allowance rate for applications examined by JONES-FOSTER, ERICA NICOLE. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.4% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 38.9% of cases where such amendments are filed. This entry rate is in the 59% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Petition Practice

When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.